Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio (NASDAQ:ESPR)

Core Insights - Esperion Therapeutics (ESPR) reported that 2025 was a transformative year, showcasing the company's strongest performance to date [2] - The company emphasized its commitment to fortifying its financial foundation and enhancing commercial execution [2] Financial Performance - Esperion aims to target operating expenses of up to $255 million by 2026 while expanding its cardiometabolic portfolio [2] Strategic Initiatives - The acquisition of Corstasis is part of Esperion's Vision 2040, indicating a long-term strategy for growth and innovation in the cardiometabolic space [2]